{"id":"NCT00466167","sponsor":"Boehringer Ingelheim","briefTitle":"Pivotal Study in Advanced Parkinsons Disease Patients","officialTitle":"A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2008-11","completion":null,"firstPosted":"2007-04-27","resultsPosted":"2010-02-08","lastUpdate":"2014-07-08"},"enrollment":517,"design":{"allocation":null,"model":"PARALLEL","masking":null,"primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"Pramipexol Extended Release","otherNames":[]},{"type":"DRUG","name":"Pramipexol Immediate Release","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pramipexole ER","type":"OTHER"},{"label":"Pramipexole IR","type":"OTHER"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined), safety, and tolerability of pramipexole ER, in daily doses from 0.375 milligram to 4.5 milligram once a day, in comparison to placebo, in Levodopa combined with a Dopa-Decarboxylase-inhibitor treated Parkinson patients with advanced Parkinsons Disease and motor fluctuations.\n\nIn addition, a numerical comparison of the efficacy of pramipexole extended release versus pramipexole immediate release will be done.\n\nThe efficacy of pramipexole immediate release will also be compared to placebo, for assay sensitivity.","primaryOutcome":{"measure":"Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18","timeFrame":"baseline and week 18","effectByArm":[{"arm":"Pramipexole ER","deltaMin":-11,"sd":1},{"arm":"Pramipexole IR","deltaMin":-12.8,"sd":0.9},{"arm":"Placebo","deltaMin":-6.1,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0001"},{"comp":"OG001 vs OG002","p":"<.0001"}]},"eligibility":{"minAge":"32 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":76,"countries":["Austria","Czechia","Hungary","India","Italy","Philippines","Poland","Russia","Slovakia","South Korea","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":178},"commonTop":["Somnolence","Dyskinesia","Nausea","Dizziness","Constipation"]}}